Clinical trials
Recurrent or Metastatic Solid Tumors clinical trials
Below are recruiting recurrent or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,362 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03661307RecruitingPhase 1/Phase 2
Quizartinib, decitabine, and venetoclax for AML or high-risk MDS
This early-phase trial studies a 3-drug combination to treat certain types of acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) in adults. It may help by targeting cancer cells using different medicines, especially for people who may not be able to get intensive chemotherapy.
Houston, TexasAges 18 years+ - NCT07197671RecruitingPhase 1
Radiation drug for people with head and neck cancer on immunotherapy
This study tests a radioactive drug called Y-NM600 that may help treat head and neck cancer that has spread. It is given to people who are already receiving an immunotherapy drug (like Keytruda or Opdivo) and whose cancer is stable or slightly growing.
Madison, WisconsinAges 18 years+ - NCT07214298RecruitingPhase 1/Phase 2
Combination treatment for advanced pancreatic cancer
This trial tests a new drug, pegcetacoplan, combined with a standard chemotherapy regimen called modified FOLFIRINOX, for people with pancreatic cancer that has spread to other parts of the body. The goal is to see if the combination helps control the cancer better than chemotherapy alone.
Buffalo, New YorkAges 18 years+ - NCT07017829RecruitingPhase 2
Combination therapy for STK11-mutant lung cancer
This trial tests a new drug (GT103) combined with the approved immunotherapy drug pembrolizumab for people with advanced lung cancer that has a specific genetic change (STK11). The goal is to see if adding GT103 helps control the cancer better than pembrolizumab alone.
Buffalo, New YorkAges 18 years+ - NCT07492641RecruitingPhase 3
A new drug plus letrozole for advanced HR+ breast cancer
This trial tests a new medicine (BGB-43395) combined with letrozole against the usual CDK4/6 inhibitor plus letrozole. It is for people with advanced or metastatic HR-positive, HER2-negative breast cancer who have not yet had treatment for advanced disease.
Birmingham, AlabamaAges 18 years+ - NCT05361720RecruitingPhase 2
Genetic test to match treatment for advanced kidney cancer
This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.
Duarte, CaliforniaAges 18 years+ - NCT07050186RecruitingPhase 2
Cemiplimab for advanced NUT carcinoma
This trial tests a drug called cemiplimab for people with NUT carcinoma that has spread or cannot be removed. The drug aims to shrink tumors or slow their growth.
Chicago, IllinoisAges 18 years+ - NCT04485559RecruitingPhase 1
Trametinib and everolimus for recurrent gliomas
This trial tests two drugs, trametinib and everolimus, for children and young adults with recurrent or progressive gliomas (a type of brain tumor). The goal is to see if this drug combination is safe and effective in treating these tumors.
Birmingham, AlabamaAges 1–25 - NCT07233278Recruiting
Brain stimulation for anxiety after miscarriages
This study tests a non-invasive brain stimulation technique (repetitive TMS) to see if it can improve heart health and reduce anxiety in women who have had multiple pregnancy losses and struggle with anxiety. You will receive high-intensity, low-frequency magnetic pulses over a specific area of the brain involved in worry and stress.
Shenyang, LiaoningAges 18–45 - NCT05902169RecruitingPhase 3
Ultrasound with carboplatin for recurrent glioblastoma
This trial tests a device that opens the blood-brain barrier using ultrasound, allowing chemotherapy to reach the brain tumor better. It compares this approach to standard chemotherapy for people whose glioblastoma has returned.
Phoenix, ArizonaAges 18 years+ - NCT07544056RecruitingPhase 2/Phase 3
BEBT-209 Plus Chemotherapy for Triple-Negative Breast Cancer
This study tests a new drug called BEBT-209 combined with chemotherapy (carboplatin and gemcitabine) in women with advanced triple-negative breast cancer that has spread or cannot be surgically removed. The goal is to see if this combination can slow or stop cancer growth better than standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT07221357RecruitingPhase 2/Phase 3
Pumitamig plus chemo vs standard care for new colorectal cancer
This trial tests a new drug called Pumitamig combined with chemotherapy against standard bevacizumab plus chemotherapy for people with advanced colorectal cancer that cannot be surgically removed and hasn't been treated yet. The goal is to see which combination works better and is safer.
Tucson, ArizonaAges 18 years+ - NCT07759921Recruiting
Mindfulness program for couples facing metastatic colorectal cancer
This study tests a mindfulness-based program for couples facing metastatic colorectal cancer. It aims to help reduce distress and improve coping for both patients and their partners.
Aurora, ColoradoAges 18–85 - NCT07629258RecruitingPhase 1
Testing GW01-200 tablets in advanced cancer patients
This is an early-stage trial testing a new drug called GW01-200 in people with advanced solid tumors or blood cancers that have gotten worse despite standard treatment. The study aims to find the right dose and see how well the drug works and is tolerated.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05650749Enrolling by invitationPhase 1
GPC2 car T cells for neuroblastoma and retinoblastoma
This trial tests a new treatment using engineered immune cells (CAR T cells) that target a protein called GPC2 found on some cancer cells. It is for patients with high-risk neuroblastoma or metastatic retinoblastoma that has returned or not responded to other treatments.
Philadelphia, PennsylvaniaAges 1 year+ - NCT07150806RecruitingPhase 1/Phase 2
RYZ101 for progressive or recurrent meningioma
This trial is testing an investigational drug, RYZ101, for people with a type of brain tumor called meningioma that has grown back or not responded to other treatments. The goal is to see if RYZ101 can help stop the tumor from growing, and to check its safety. It might be an option if you have already had surgery or radiation.
Columbus, OhioAges 18 years+ - NCT07513285RecruitingPhase 2
Ibezapolstat pill for recurrent C. difficile infection
This trial tests a new oral antibiotic called ibezapolstat to treat recurrent C. difficile infection (CDI)—a serious diarrheal illness caused by bacteria in your gut. The study focuses on patients who have had multiple CDI episodes and may benefit from a different treatment approach.
Sacramento, CaliforniaAges 18–90 - NCT06589440RecruitingPhase 2
Study of SR-8541A plus two immunotherapies for advanced colorectal cancer
This trial tests a new drug combination (SR-8541A, botensilimab, and balstilimab) for people with a specific type of metastatic colorectal cancer that is not MSI-high. It aims to see if this combination can help when other treatments have stopped working.
Morristown, New JerseyAges 18 years+ - NCT03424005RecruitingPhase 1/Phase 2
Testing new drug combinations for advanced breast cancer
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
Duarte, CaliforniaAges 18 years+ - NCT05417594RecruitingPhase 1/Phase 2
Targeted drug study for advanced cancers with genetic changes
This Phase 1/2 study tests AZD9574 alone or with other cancer treatments in people with advanced solid tumors. It focuses on cancers with specific DNA repair gene changes (like BRCA1/2) or other matching tumor features, and aims to see if the treatment can shrink tumors and improve outcomes.
La Jolla, CaliforniaAges 18–130 - NCT06696768RecruitingPhase 1
New drug plus standard chemotherapy for advanced colorectal cancer
This trial combines a new experimental drug (emavusertib) with standard chemotherapy (FOLFOX plus bevacizumab) for people with stage IV colorectal cancer who have not yet received chemotherapy. The goal is to see if the combination is safe and effective, potentially offering a new first-line treatment option.
Gainesville, FloridaAges 18 years+ - NCT07347600Recruiting
Studying inavolisib for a type of advanced breast cancer
This study tests a targeted therapy called inavolisib for people whose breast cancer has spread (advanced or metastatic), is hormone receptor-positive and HER2-negative, has a PIK3CA mutation, and has stopped responding to hormone therapy. It aims to see if inavolisib is safe and works well for them.
Xiamen, FujianAges 18 years+ - NCT07074756Recruiting
Home-based treatment support for people with glioma
This study tests a digital platform that helps you manage your glioma treatment at home. It aims to make it easier to follow your treatment plan and stay connected with your care team.
Jacksonville, FloridaAges 18 years+ - NCT07159048Recruiting
Heat therapy for liver tumors
This trial tests a heat-based treatment for liver cancer tumors that uses multiple methods to destroy cancer cells. It may help people with liver tumors that haven't spread and who are healthy enough for treatment.
Shanghai, Shanghai MunicipalityAges 18–80
Hear when a new Recurrent or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic solid tumors?
- Yes. Clin2 currently lists 3,362 recruiting recurrent or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.